Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
, 21 (10), 52

Maneuvering Clinical Pathways for Ulcerative Colitis

Affiliations
Review

Maneuvering Clinical Pathways for Ulcerative Colitis

Christopher M Johnson et al. Curr Gastroenterol Rep.

Abstract

Purpose of review: Recent years have brought about several advances in the treatment of patients with ulcerative colitis (UC). Here, we discuss salient recommendations of recent treatment guidelines; review the efficacy, safety, and real-world data of vedolizumab and tofacitinib; appraise their place vis-à-vis established agents; and consider the newly proposed approaches of risk-stratified and treat-to-target therapy.

Recent findings: Once daily oral mesalamine dosing is equivalent to split dosing in mild-moderate UC. Real-world data are accumulating on the effectiveness and safety of vedolizumab for moderate to severe UC, while there are few such data on the most recently approved agent, tofacitinib. High-dose infliximab is being investigated for severe UC. New approaches are challenging the established paradigm of selecting therapy based on current disease activity. The risk-stratified approach incorporates long-term risk as well as the current burden of inflammation. The treat-to-target approach aims at improved long-term outcomes by adjusting therapy to resolve intestinal inflammation. The therapeutic options for UC are continually expanding. Risk-stratified therapy and the treat-to-target approach represent paradigm shifts in UC management. Optimal disease control requires an individualized approach that takes into consideration current inflammatory burden, long-term risk, patient preferences, and ongoing assessment of response to treatment.

Keywords: Inflammatory bowel disease; Tofacitinib; Ulcerative colitis; Vedolizumab.

Similar articles

See all similar articles

Cited by 1 PubMed Central articles

References

    1. Am J Gastroenterol. 1997 Jul;92(7):1143-7 - PubMed

References

    1. Gastroenterology. 2004 Feb;126(2):451-9 - PubMed

References

    1. Am J Gastroenterol. 2018 Sep;113(9):1345 - PubMed

References

    1. Inflamm Bowel Dis. 2017 Dec;23(12):2197-2201 - PubMed

References

    1. MMWR Morb Mortal Wkly Rep. 2018 Jan 26;67(3):103-108 - PubMed

References

    1. Aliment Pharmacol Ther. 2014 Sep;40(5):486-97 - PubMed

References

    1. Aliment Pharmacol Ther. 2018 Jan;47(2):162-175 - PubMed

References

    1. Aliment Pharmacol Ther. 2018 Oct;48(8):839-851 - PubMed

References

    1. Clin Infect Dis. 2019 Mar 07;:null - PubMed

References

    1. Gastroenterology. 2019 Feb;156(3):748-764 - PubMed

References

    1. Gastrointest Endosc. 2018 Dec;88(6):887-898 - PubMed

References

    1. Am J Gastroenterol. 2018 Aug;113(8):1197-1205 - PubMed

References

    1. Clin Gastroenterol Hepatol. 2019 Oct;17(11):2374-2376.e2 - PubMed

References

    1. Clin Gastroenterol Hepatol. 2019 Jan;17(1):139-147 - PubMed

References

    1. J Crohns Colitis. 2019 Jan 1;13(1):50-57 - PubMed

References

    1. Gastroenterology. 2018 Sep;155(3):687-695.e10 - PubMed

References

    1. Clin Gastroenterol Hepatol. 2016 Sep;14(9):1245-1255.e8 - PubMed

References

    1. J Crohns Colitis. 2017 Aug 1;11(8):921-929 - PubMed

References

    1. Gastroenterology. 2019 Apr;156(5):1508-1524 - PubMed

References

    1. Gut. 2017 May;66(5):839-851 - PubMed

References

    1. Drug Saf. 2018 Apr;41(4):357-361 - PubMed

References

    1. Am J Gastroenterol. 2015 Sep;110(9):1324-38 - PubMed

References

    1. Aliment Pharmacol Ther. 2017 Mar;45(5):617-630 - PubMed

References

    1. Clin Gastroenterol Hepatol. 2011 Jun;9(6):483-489.e3 - PubMed

References

    1. N Engl J Med. 2013 Aug 22;369(8):699-710 - PubMed

References

    1. Inflamm Bowel Dis. 2018 Sep 15;24(10):2258-2265 - PubMed

References

    1. N Engl J Med. 2017 May 4;376(18):1723-1736 - PubMed

References

    1. Gastroenterology. 2012 Nov;143(5):1218-1226.e2 - PubMed

References

    1. Am J Gastroenterol. 2019 Jul;114(7):1172-1175 - PubMed

References

    1. Ocul Immunol Inflamm. 2019;27(8):1232-1234 - PubMed

References

    1. J Crohns Colitis. 2017 Jul 1;11(7):785-791 - PubMed

References

    1. Clin Gastroenterol Hepatol. 2019 Apr;17(5):988-990.e1 - PubMed

References

    1. Inflamm Bowel Dis. 2017 May;23(5):822-832 - PubMed

References

    1. J Crohns Colitis. 2017 Jul 1;11(7):769-784 - PubMed

References

    1. Aliment Pharmacol Ther. 2019 Feb;49(4):408-418 - PubMed

References

    1. Inflamm Bowel Dis. 2018 Apr 23;24(5):1099-1105 - PubMed

References

    1. J Crohns Colitis. 2017 Jun 1;11(6):649-670 - PubMed

References

    1. Aliment Pharmacol Ther. 2019 Apr;49(7):873-879 - PubMed

References

    1. Inflamm Bowel Dis. 2007 Sep;13(9):1115-20 - PubMed

References

    1. Gut. 2019 Jun;68(6):977-984 - PubMed

References

    1. Inflamm Bowel Dis. 2018 Nov 29;24(12):2494-2500 - PubMed

References

    1. Clin Gastroenterol Hepatol. 2019 Apr;17(5):838-846.e2 - PubMed

References

    1. Clin Pharmacokinet. 2017 Nov;56(11):1287-1301 - PubMed

References

    1. Gut. 2019 Jan;68(1):25-39 - PubMed

References

    1. Gastroenterology. 2011 Oct;141(4):1194-201 - PubMed

References

    1. Am J Gastroenterol. 2019 Mar;114(3):384-413 - PubMed

References

    1. Clin Gastroenterol Hepatol. 2019 Jul;17(8):1541-1550 - PubMed

References

    1. Inflamm Bowel Dis. 2012 Sep;18(9):1634-40 - PubMed

References

    1. Inflamm Bowel Dis. 2013 Mar-Apr;19(4):779-84 - PubMed

References

    1. Gastrointest Endosc. 2017 Dec;86(6):1006-1011.e8 - PubMed

References

    1. Patient Prefer Adherence. 2017 Feb 22;11:297-303 - PubMed

References

    1. Clin Gastroenterol Hepatol. 2019 Jul;17(8):1533-1540.e2 - PubMed

References

    1. Dig Dis Sci. 2019 Jul;64(7):1945-1951 - PubMed

References

    1. J Crohns Colitis. 2019 Jan 1;13(1):12-18 - PubMed

References

    1. Inflamm Bowel Dis. 2018 Sep 15;24(10):2173-2182 - PubMed

References

    1. Clin Gastroenterol Hepatol. 2019 Feb;17(3):502-509.e1 - PubMed

References

    1. Inflamm Bowel Dis. 2018 Apr 13;:null - PubMed

References

    1. N Engl J Med. 2005 Dec 8;353(23):2462-76 - PubMed

References

    1. Aliment Pharmacol Ther. 2018 Sep;48(6):626-637 - PubMed

References

    1. Am J Physiol Gastrointest Liver Physiol. 2016 Feb 1;310(3):G155-62 - PubMed

References

    1. Gastroenterology. 2019 Feb;156(3):769-808.e29 - PubMed

References

    1. PLoS One. 2016 Feb 26;11(2):e0149692 - PubMed

References

    1. Am J Ophthalmol Case Rep. 2018 Dec 04;13:53-55 - PubMed

References

    1. Gastrointest Endosc Clin N Am. 2014 Jul;24(3):367-78 - PubMed

References

    1. Gastroenterology. 2015 Jul;149(1):238-45 - PubMed

References

    1. J Crohns Colitis. 2017 Oct 27;11(11):1353-1361 - PubMed

References

    1. Aliment Pharmacol Ther. 2006 Mar 1;23(5):577-85 - PubMed

References

    1. Aliment Pharmacol Ther. 2015 Jul;42(2):188-202 - PubMed

References

    1. Dig Dis Sci. 2017 Feb;62(2):481-490 - PubMed

References

    1. Gastroenterology. 2007 Aug;133(2):412-22 - PubMed

References

    1. Inflamm Bowel Dis. 2019 Jun 18;25(7):1169-1186 - PubMed

References

    1. Gut. 2014 Mar;63(3):433-41 - PubMed

References

    1. Eur J Health Econ. 2019 Mar;20(2):195-203 - PubMed

References

    1. Clin Gastroenterol Hepatol. 2019 Jan;17(1):130-138.e7 - PubMed

References

    1. Clin Gastroenterol Hepatol. 2019 May 8;:null - PubMed

References

    1. Am J Gastroenterol. 2017 Sep;112(9):1423-1429 - PubMed

References

    1. Clin Gastroenterol Hepatol. 2019 Apr;17(5):991-993 - PubMed

References

    1. Aliment Pharmacol Ther. 2017 Apr;45(7):941-950 - PubMed

LinkOut - more resources

Feedback